Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
SOUTH SAN FRANCISCO, Calif., March 01, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the Cowen and Company 36th Annual Health Care Conference 2016. Susan M. Molineaux, Ph.D., the company’s Founder, President and Chief Executive Officer, will present on Tuesday, March 8, 2016 at 11:20 a.m. Eastern Time in Boston, Massachusetts. The presentation will be webcast live and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Contact: Jennifer McNealey [email protected] 650-870-1071
